Business Context and Reporting Period
Company: Hyperliquid Strategies Inc (Ticker: PURR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2025 (Inception: July 2, 2025)
Business Status: The Company was formed for the purpose of effecting a business combination (the "Transaction"). As of the reporting date, the Company had not generated any revenues. All activity related to formation and preparation for the Transaction. The Transaction with Sonnet BioTherapeutics Holdings, Inc. and Rorschach Cayman LLC closed on December 2, 2025 (a subsequent event).
Key Financial Metrics
| Metric | Value (Inception to Sept 30, 2025) |
|---|---|
| Revenue | $0 |
| Net Loss | $(1,212,921) |
| Formation & Operating Costs | $(1,212,921) |
| Cash and Cash Equivalents | $0 |
| Total Current Liabilities | $1,212,921 |
| Stockholder's Deficit | $(1,212,921) |
| Weighted Average Shares Outstanding | 92 |
| Net Loss Per Share | $(13,183.92) |
Material Changes and Subsequent Events
The financial statements reflect a pre-transaction shell company with no operating history. Significant changes occurred subsequent to the balance sheet date:
- Transaction Closing: On December 2, 2025, the Company completed the merger with Sonnet BioTherapeutics and Rorschach Cayman LLC.
- Capital Raised: Concurrent with the closing, the Company received approximately $299.9 million in cash and 12.5 million HYPE tokens.
- Going Concern: The substantial doubt regarding the Company's ability to continue as a going concern, noted in prior filings, has been alleviated by the capital raised in the Transaction.
- Stock Trading: Common stock began trading on the Nasdaq Capital Market under the symbol "PURR" on December 3, 2025.
- Repurchase Program: On December 8, 2025, the Board authorized a $30 million stock repurchase program.
Outlook, Risks, and Management Commentary
Strategy: Post-transaction, the Company initiated a "HYPE treasury strategy," holding cash and HYPE tokens (native cryptocurrency of the Hyperliquid protocol). Management expects existing resources to fund operations for the next twelve months.
Risks and Contingencies:
- Cryptocurrency Volatility: Financial condition is substantially dependent on the market price and liquidity of HYPE tokens, which are subject to extreme volatility.
- Protocol Dependency: Value of treasury holdings depends on the success and adoption of the Hyperliquid protocol.
- Financing Uncertainty: While capital was raised, future funding for working capital is not guaranteed and may not be available on acceptable terms.
- Contingent Value Rights (CVRs): Former Sonnet shareholders received CVRs payable upon the monetization of legacy assets within three years of the closing.
At-the-Market Facility: On October 22, 2025, the Company entered an agreement with Chardan Capital Markets to sell up to $1 billion of common stock over time.
Investor Verification Checklist
- Transaction Completion: Verify the final closing details and the exact amount of cash and HYPE tokens received as of the December 2, 2025 closing date.
- HYPE Token Valuation: Assess the current market price and liquidity of HYPE tokens to understand the volatility risk to the Company's treasury assets.
- Capital Structure: Review the dilution impact of the 127 million common shares, Series A Preferred Stock, Advisor Warrants, and CVRs outstanding post-closing.
- Related Party Transactions: Examine the Advisor Rights Agreement and the 5% equity/15% warrant entitlement for the Advisor on future financings.
- Legacy Assets: Investigate the nature of "Company Legacy Assets" tied to the CVR payments to understand potential future cash flow obligations.